Ozempic and Wegovy make the list of the next 15 drugs in Medicare negotiations: HHS
Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer treatment Calquence, GSK’s chronic obstructive pulmonary disorder (COPD) drug Breo Ellipta, and AbbVie’s antipsychotic medication Vraylar.
Meena Seshamani’s Medicare swan song ended on a note of bravura: the announcement that 15 costly drugs, including Novo ...
The rescinded order directed Medicare and Medicaid to test ways to lower drug costs for enrollees. Those tests hadn’t started ...
As of Monday, FDA commissioner Robert Califf, Department of Health and Human Services (HHS) Secretary Xavier Becerra, ...
Abe Sutton, a health policy aide in the first Trump administration, is likely to be named head of the Center for Medicare and ...
Paul Mango, a senior health official during President-elect Donald Trump's first term who was a member of Trump's current ...
Xavier Becerra is reflecting on tenure as HHS secretary. He told Scripps News, "We're leaving this country healthier and ...
Last June, the Supreme Court issued its decision in Securities and Exchange Commission v. Jarkesy, which holds that the ...
A new Health and Human Services report is calling for greater transparency in long-term care ownership, calling out private ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback